Assessing an Oral SERD, DZD3969 in Patients With Advanced ER+HER2- Breast Cancer (MU-LAN1)
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study will treat patients with advanced ER+HER2- breast cancer who have progressed
following prior therapy. This is the first time this drug has ever been tested in patients,
and so it will help to understand what type of side effects may occur with this new drug. It
will also measure the levels of drug in the body and preliminarily assess its anti-cancer
activity as alone and in combination with Palbociclib